lumateperone 21 MG (as lumateperone tosylate 30 MG) Oral Capsule
- RxCUI
- 2607533
- RxNorm name
- lumateperone 21 MG (as lumateperone tosylate 30 MG) Oral Capsule
- Display name
- lumateperone 21 MG (as lumateperone tosylate 30 MG) Oral Capsule
- Full name
- lumateperone 21 MG (as lumateperone tosylate 30 MG) Oral Capsule
- Term type
- SY
- Status
- DailyMed mapping
- Updated
- 2026-06-04 23:39:23
UNII Substances#
No records found.
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| CAPLYTA | LUMATEPERONE | Intra-Cellular Therapies, Inc | db730b06-6351-47fd-8183-e61e61bbead5 | 2025-06-20 | Boxed warning, Warnings, Adverse reactions | 2607533 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
DailyMed RxNorm Mappings#
| Set ID | RxNorm mappings | Terms | SPL version | Label | Effective |
|---|---|---|---|---|---|
| db730b06-6351-47fd-8183-e61e61bbead5 | lumateperone 21 MG Oral Capsule [PSN] · lumateperone 21 MG Oral Capsule [SCD] · lumateperone 21 MG (as lumateperone tosylate 30 MG) Oral Capsule [SY] | 3 | 27 | These highlights do not include all the information needed to use CAPLYTA safely and effectively. See full prescribing information for CAPLYTA. CAPLYTA ® (lumateperone) capsules, for oral use Initial U.S. Approval: 2019 | 20250620 |